FDA approves Kerendia for heart failure with ejection fraction of 40% or higher

Following priority review, the U.S. Food and Drug Administration approved Bayer’s Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup